Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Suppressive effects of whey protein hydrolysate on sucrose-induced hyperglycemia in silkworms.

Matsumoto Y, Takahashi M, Umehara M, Asano M, Maruki-Uchida H, Morita M, Sekimizu K.

Drug Discov Ther. 2019 Nov 14;13(5):244-247. doi: 10.5582/ddt.2019.01069. Epub 2019 Oct 14.

2.

Detection of Trichophyton spp. from footwear of patients with tinea pedis.

Ishijima SA, Hiruma M, Sekimizu K, Abe S.

Drug Discov Ther. 2019;13(4):207-211. doi: 10.5582/ddt.2019.01060.

3.

Identification of 2H phosphoesterase superfamily proteins with 2'-CPDase activity.

Mitsutomi S, Akimitsu N, Sekimizu K, Kaito C.

Biochimie. 2019 Oct;165:235-244. doi: 10.1016/j.biochi.2019.08.008. Epub 2019 Aug 15.

PMID:
31422053
4.

Complete Genome Sequence of Weissella hellenica 0916-4-2 and Its Comparative Genomic Analysis.

Panthee S, Paudel A, Blom J, Hamamoto H, Sekimizu K.

Front Microbiol. 2019 Jul 24;10:1619. doi: 10.3389/fmicb.2019.01619. eCollection 2019.

6.

Development of a high-throughput strategy for discovery of potent analogues of antibiotic lysocin E.

Itoh H, Tokumoto K, Kaji T, Paudel A, Panthee S, Hamamoto H, Sekimizu K, Inoue M.

Nat Commun. 2019 Jul 5;10(1):2992. doi: 10.1038/s41467-019-10754-4.

7.

Pharmacokinetics of anti-infectious reagents in silkworms.

Hamamoto H, Horie R, Sekimizu K.

Sci Rep. 2019 Jul 1;9(1):9451. doi: 10.1038/s41598-019-46013-1.

8.

Molecular characterization of multi-drug resistant coagulase negative cocci in non-hospital environment.

Nwibo DD, Panthee S, Hamamoto H, Sekimizu K.

Drug Discov Ther. 2019 Jul 22;13(3):145-149. doi: 10.5582/ddt.2019.01031. Epub 2019 Jun 23.

9.

Staphylococcus aureus aggregation in the plasma fraction of silkworm hemolymph.

Ryuno H, Nigo F, Naguro I, Sekimizu K, Kaito C.

PLoS One. 2019 May 30;14(5):e0217517. doi: 10.1371/journal.pone.0217517. eCollection 2019.

10.

Enterococcus faecalis YM0831 suppresses sucrose-induced hyperglycemia in a silkworm model and in humans.

Matsumoto Y, Ishii M, Hasegawa S, Sekimizu K.

Commun Biol. 2019 May 2;2:157. doi: 10.1038/s42003-019-0407-5. eCollection 2019.

11.

Silkworm as an experimental animal for research on fungal infections.

Matsumoto Y, Sekimizu K.

Microbiol Immunol. 2019 Feb;63(2):41-50. doi: 10.1111/1348-0421.12668. Epub 2019 Feb 14. Review.

12.

Establishment of a gnotobiotic silkworm model.

Nakajima H, Matsumoto Y, Sekimizu K.

Drug Discov Ther. 2018;12(5):291-294. doi: 10.5582/ddt.2018.01048.

13.

Bacterial polysaccharides inhibit sucrose-induced hyperglycemia in silkworms.

Ishii M, Matsumoto Y, Sekimizu K.

Drug Discov Ther. 2018 Sep 18;12(4):185-188. doi: 10.5582/ddt.2018.01040. Epub 2018 Aug 24.

14.

Utilization of Hybrid Assembly Approach to Determine the Genome of an Opportunistic Pathogenic Fungus, Candida albicans TIMM 1768.

Panthee S, Hamamoto H, Ishijima SA, Paudel A, Sekimizu K.

Genome Biol Evol. 2018 Aug 1;10(8):2017-2022. doi: 10.1093/gbe/evy166.

15.

Loss of DDHD2, whose mutation causes spastic paraplegia, promotes reactive oxygen species generation and apoptosis.

Maruyama T, Baba T, Maemoto Y, Hara-Miyauchi C, Hasegawa-Ogawa M, Okano HJ, Enda Y, Matsumoto K, Arimitsu N, Nakao K, Hamamoto H, Sekimizu K, Ohto-Nakanishi T, Nakanishi H, Tokuyama T, Yanagi S, Tagaya M, Tani K.

Cell Death Dis. 2018 Jul 23;9(8):797. doi: 10.1038/s41419-018-0815-3.

16.

Inhibitory effects of alpha-cyclodextrin and its derivative against sucrose-induced hyperglycemia in an in vivo evaluation system.

Ishii M, Matsumoto Y, Sekimizu K.

Drug Discov Ther. 2018;12(3):122-125. doi: 10.5582/ddt.2018.01028.

17.

[Development of Antibiotics Using Silkworm Bacteria and Fungi Infection Model].

Hamamoto H, Sekimizu K.

Yakugaku Zasshi. 2018;138(7):895-899. doi: 10.1248/yakushi.17-00202-4. Review. Japanese.

18.

[Platform Development for Drug Discovery Utilizing Silkworm towards "Novel Industrial Revolution"].

Sekimizu K, Itoh K.

Yakugaku Zasshi. 2018;138(7):861-862. doi: 10.1248/yakushi.17-00202-F. Japanese. No abstract available.

19.

Estimation of lactic acid bacterial cell number by DNA quantification.

Ishii M, Matsumoto Y, Sekimizu K.

Drug Discov Ther. 2018;12(2):88-91. doi: 10.5582/ddt.2018.01019.

20.

Pharmacokinetic parameters explain the therapeutic activity of antimicrobial agents in a silkworm infection model.

Paudel A, Panthee S, Urai M, Hamamoto H, Ohwada T, Sekimizu K.

Sci Rep. 2018 Jan 25;8(1):1578. doi: 10.1038/s41598-018-19867-0.

21.

[A Silkworm Infection Model to Evaluate Antifungal Drugs for Cryptococcosis].

Matsumoto Y, Ishii M, Shimizu K, Kawamoto S, Sekimizu K.

Med Mycol J. 2017;58(4):E131-E137. doi: 10.3314/mmj.17.016. Japanese.

22.

Evaluation of the innate immune-stimulating activity of amazake using a silkworm muscle contraction assay.

Maruki-Uchida H, Sai M, Sekimizu K.

Drug Discov Ther. 2017 Nov 22;11(5):288-290. doi: 10.5582/ddt.2017.01051. Epub 2017 Oct 30.

23.

Isolation of antibiotic-producing Pseudomonas species with low-temperature cultivation of temperate soil.

Mitsutomi S, Sekimizu K, Kaito C.

Drug Discov Ther. 2017 Nov 22;11(5):267-275. doi: 10.5582/ddt.2017.01053. Epub 2017 Oct 29.

24.

Two-spotted cricket as an animal infection model of human pathogenic fungi.

Kochi Y, Matsumoto Y, Sekimizu K, Kaito C.

Drug Discov Ther. 2017 Nov 22;11(5):259-266. doi: 10.5582/ddt.2017.01052. Epub 2017 Oct 29.

25.

Characterization of the chemical structure and innate immune-stimulating activity of an extracellular polysaccharide from Rhizobium sp. strain M2 screened using a silkworm muscle contraction assay.

Urai M, Aizawa T, Imamura K, Hamamoto H, Sekimizu K.

Drug Discov Ther. 2017 Nov 22;11(5):238-245. doi: 10.5582/ddt.2017.01045. Epub 2017 Oct 11.

26.

Structural analysis of an innate immunostimulant from broccoli, Brassica oleracea var. italica.

Urai M, Kataoka K, Nishida S, Sekimizu K.

Drug Discov Ther. 2017 Nov 22;11(5):230-237. doi: 10.5582/ddt.2017.01044. Epub 2017 Oct 11.

27.

Total Synthesis and Biological Mode of Action of WAP-8294A2: A Menaquinone-Targeting Antibiotic.

Itoh H, Tokumoto K, Kaji T, Paudel A, Panthee S, Hamamoto H, Sekimizu K, Inoue M.

J Org Chem. 2018 Jul 6;83(13):6924-6935. doi: 10.1021/acs.joc.7b02318. Epub 2017 Nov 7.

PMID:
29019678
28.

An invertebrate infection model for evaluating anti-fungal agents against dermatophytosis.

Ishii M, Matsumoto Y, Yamada T, Abe S, Sekimizu K.

Sci Rep. 2017 Sep 25;7(1):12289. doi: 10.1038/s41598-017-12523-z.

29.

Unified Total Synthesis of Polyoxins J, L, and Fluorinated Analogues on the Basis of Decarbonylative Radical Coupling Reactions.

Fujino H, Nagatomo M, Paudel A, Panthee S, Hamamoto H, Sekimizu K, Inoue M.

Angew Chem Int Ed Engl. 2017 Sep 18;56(39):11865-11869. doi: 10.1002/anie.201706671. Epub 2017 Aug 17.

PMID:
28727238
30.

D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.

Tabuchi F, Matsumoto Y, Ishii M, Tatsuno K, Okazaki M, Sato T, Moriya K, Sekimizu K.

J Antibiot (Tokyo). 2017 Jul;70(8):907-910. doi: 10.1038/ja.2017.56. Epub 2017 Jun 7.

PMID:
28588223
31.

Draft Genome Sequence of the Vancomycin-Resistant Clinical Isolate Staphylococcus aureus VRS3b.

Panthee S, Paudel A, Hamamoto H, Sekimizu K.

Genome Announc. 2017 Jun 1;5(22). pii: e00452-17. doi: 10.1128/genomeA.00452-17.

32.

A Novel Spiro-Heterocyclic Compound Identified by the Silkworm Infection Model Inhibits Transcription in Staphylococcus aureus.

Paudel A, Hamamoto H, Panthee S, Kaneko K, Matsunaga S, Kanai M, Suzuki Y, Sekimizu K.

Front Microbiol. 2017 Apr 25;8:712. doi: 10.3389/fmicb.2017.00712. eCollection 2017.

33.

Genomic analysis of vancomycin-resistant Staphylococcus aureus VRS3b and its comparison with other VRSA isolates.

Panthee S, Hamamoto H, Paudel A, Sekimizu K.

Drug Discov Ther. 2017 May 30;11(2):78-83. doi: 10.5582/ddt.2017.01024. Epub 2017 Apr 30.

34.

Biological activities and antibacterial biomarker of Sesbania grandiflora bark extract.

Anantaworasakul P, Hamamoto H, Sekimizu K, Okonogi S.

Drug Discov Ther. 2017 May 30;11(2):70-77. doi: 10.5582/ddt.2017.01013. Epub 2017 Apr 30.

35.

Influence of clove oil and eugenol on muscle contraction of silkworm (Bombyx mori).

Kheawfu K, Pikulkaew S, Hamamoto H, Sekimizu K, Okonogi S.

Drug Discov Ther. 2017 May 30;11(2):64-69. doi: 10.5582/ddt.2017.01012. Epub 2017 Apr 30.

36.

The Usefulness of Silkworms as a Model Animal for Evaluating the Effectiveness of Medicine and Food.

Sekimizu K.

Yakugaku Zasshi. 2017;137(5):551-562. doi: 10.1248/yakushi.16-00249. Review. Japanese.

37.

Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis.

Yagi A, Uchida R, Hamamoto H, Sekimizu K, Kimura KI, Tomoda H.

J Antibiot (Tokyo). 2017 May;70(5):685-690. doi: 10.1038/ja.2017.23.

PMID:
28446822
38.

Development of Novel Antibiotic Lysocin E Identified by Silkworm Infection Model.

Hamamoto H, Sekimizu K.

Yakugaku Zasshi. 2017;137(4):389-392. doi: 10.1248/yakushi.16-00235-4. Review. Japanese.

39.

Lactobacillus paraplantarum 11-1 Isolated from Rice Bran Pickles Activated Innate Immunity and Improved Survival in a Silkworm Bacterial Infection Model.

Nishida S, Ishii M, Nishiyama Y, Abe S, Ono Y, Sekimizu K.

Front Microbiol. 2017 Mar 20;8:436. doi: 10.3389/fmicb.2017.00436. eCollection 2017.

40.

Advantages of the Silkworm As an Animal Model for Developing Novel Antimicrobial Agents.

Panthee S, Paudel A, Hamamoto H, Sekimizu K.

Front Microbiol. 2017 Mar 7;8:373. doi: 10.3389/fmicb.2017.00373. eCollection 2017. Review.

41.

In vitro antibacterial activity and in vivo therapeutic effect of Sesbania grandiflora in bacterial infected silkworms.

Anantaworasakul P, Hamamoto H, Sekimizu K, Okonogi S.

Pharm Biol. 2017 Dec;55(1):1256-1262. doi: 10.1080/13880209.2017.1297467.

42.

Silkworm fungal infection model for identification of virulence genes in pathogenic fungus and screening of novel antifungal drugs.

Ishii M, Matsumoto Y, Nakamura I, Sekimizu K.

Drug Discov Ther. 2017 Mar 22;11(1):1-5. doi: 10.5582/ddt.2016.01080. Epub 2017 Feb 21.

43.

Decreased sugar concentration in vegetable and fruit juices by growth of functional lactic acid bacteria.

Ishii M, Matsumoto Y, Nishida S, Sekimizu K.

Drug Discov Ther. 2017 Mar 22;11(1):30-34. doi: 10.5582/ddt.2016.01079. Epub 2017 Feb 14.

44.

Lactic acid bacteria of the Leuconostoc genus with high innate immunity-stimulating activity.

Ishii M, Nishida S, Kataoka K, Nishiyama Y, Abe S, Sekimizu K.

Drug Discov Ther. 2017 Mar 22;11(1):25-29. doi: 10.5582/ddt.2016.01078. Epub 2017 Feb 14.

45.

Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.

Tabuchi F, Matsumoto Y, Ishii M, Tatsuno K, Okazaki M, Sato T, Moriya K, Sekimizu K.

J Antibiot (Tokyo). 2017 Jun;70(6):771-774. doi: 10.1038/ja.2017.7. Epub 2017 Feb 15.

PMID:
28196977
46.

A silkworm infection model to investigate Vibrio vulnificus virulence genes.

Yamamoto M, Kashimoto T, Yoshimura Y, Tachibana N, Kuroda S, Miki Y, Kitabayashi S, Tong P, Xiao J, Tanaka K, Hamamoto H, Sekimizu K, Yamamoto K.

Mol Med Rep. 2016 Nov;14(5):4243-4247. doi: 10.3892/mmr.2016.5782. Epub 2016 Sep 26.

PMID:
27748924
47.

Total Synthesis and Functional Evaluation of Fourteen Derivatives of Lysocin E: Importance of Cationic, Hydrophobic, and Aromatic Moieties for Antibacterial Activity.

Kaji T, Murai M, Itoh H, Yasukawa J, Hamamoto H, Sekimizu K, Inoue M.

Chemistry. 2016 Nov 14;22(47):16912-16919. doi: 10.1002/chem.201604022. Epub 2016 Oct 14.

PMID:
27739191
48.

Cell-Surface Phenol Soluble Modulins Regulate Staphylococcus aureus Colony Spreading.

Kizaki H, Omae Y, Tabuchi F, Saito Y, Sekimizu K, Kaito C.

PLoS One. 2016 Oct 10;11(10):e0164523. doi: 10.1371/journal.pone.0164523. eCollection 2016.

49.

Dividing phase-dependent cytotoxicity profiling of human embryonic lung fibroblast identifies candidate anticancer reagents.

Inagaki Y, Matsumoto Y, Tang W, Sekimizu K.

Drug Discov Ther. 2016;10(4):195-200. doi: 10.5582/ddt.2016.01049.

50.

Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection.

Nakamura I, Kanasaki R, Yoshikawa K, Furukawa S, Fujie A, Hamamoto H, Sekimizu K.

J Antibiot (Tokyo). 2017 Jan;70(1):41-44. doi: 10.1038/ja.2016.106. Epub 2016 Aug 31.

PMID:
27577982

Supplemental Content

Loading ...
Support Center